Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NMT1 | P30419 | 5/20 | 0.49 |
| ▸ | NMT2 | O60551 | 4/20 | 0.49 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9875634 | 0.88 | FOLH1 (0.66) | FOLH1SLC15A2CPB2SLC6A5GSR | |
| SCHEMBL43996 | 0.88 | FOLH1 (0.66) | FOLH1SLC15A2CPB2SLC6A5GSR | |
| SCHEMBL43995 | 0.88 | FOLH1 (0.66) | FOLH1SLC15A2CPB2SLC6A5GSR | |
| SCHEMBL29915464 | 0.88 | FOLH1 (0.51) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL29532146 | 0.88 | SLC15A2 (0.58) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL10522441 | 0.88 | GSR (0.51) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL29630712 | 0.88 | FOLH1 (0.51) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL10522423 | 0.88 | GSR (0.51) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL30881181 | 0.86 | GSR (0.50) | FOLH1NMT1NMT2SLC15A2CPB2 | |
| SCHEMBL30881170 | 0.86 | GSR (0.50) | FOLH1NMT1NMT2SLC15A2CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403419-A1 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ASTROGEN CO., LTD. (KR) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403419-A1 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | LRRK2, NLN, MAPT | FOLH1 2805/4885NMT1 1526/4885NMT2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.